Clinical characteristics of breast ductal carcinoma in situ with microinvasion: a narrative review

Zheng, Jie; Yu, Jingjing; Zhou, Tao

doi:10.1177/0300060520969304

Cited by 16 publications

(16 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From this prospective, we provided a promising tool for physicians to better introduce the individual‐based therapeutics, instead of the insufficient basis of the receptor status or pathological stage. 44 A recent study by Zhang et al also constructed a nomogram utilizing the SEER database to predict the breast cancer‐specific survival (BCSS) for MIBC patients. 45 But, the wide time span of patients' enrollment and lacking of clear information regarding molecular subtype might partially affect the reliability of the prognostic model.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population‐based analysis

Wang

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

Objectives: Microinvasive breast cancer (MIBC) is a special type of breast cancer with a relatively low prevalence, of which the understanding remains controversial. In this article, we aimed to clarify the clinicopathological characteristics and prognosis of MIBC in the setting of different molecular subtypes and give feasible suggestions on clinical practice in MIBC. Methods: This study utilized the data from Surveillance, Epidemiology, and End Results (SEER) database. Patients were divided into subgroups based on the molecular subtypes, of which the clinicopathological characteristics were further undergone comparative analyses. Kaplan-Meier method and Cox proportional hazard regression analysis were employed to determine the prognosis of the subtypes, and to explore the prognostic factors. Patients were randomly assigned in a 7:3 ratio to the training and validation cohorts. The independent risk variables were then adopted to generate a nomogram to predict the 3-and 5-year survival probability. Results: A total of 4301 MIBC patients between 2010 and 2016 were obtained from the SEER database, which were subsequently separated into HR+/HER2-(n = 2598), HR+/HER2+ (n = 723), HR-/HER2+ (n = 633), and HR-/HER2-(n = 347) groups. The HR+/HER2+ group showed the best overall survival (OS) (81.28 months, 95% CI 80.45-82.11) compared with other groups (p = 0.0089). The application of radiotherapy in HR+/HER2-and HR+/HER2+ MIBC patients brought out additional survival benefit compared with those without radiotherapy (p < 0.0001 and p = 0.024, respectively). The prognosis among four subgroups with or without chemotherapy showed no statistical difference. Based on the curated nomogram, the high-score group exhibited a better OS compared with patients from the low-score group. Conclusions: Profound heterogeneity was detected among different molecular subtypes in MIBC patients, of which HR+/HER2+ subtype presented the best prognosis. For HR-positive MIBC patients, increasing survival benefits could be

show abstract

Section: Discussionmentioning

confidence: 99%

Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population‐based analysis

Wang

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…DCIS lesions are frequently positive for the expression of human epidermal growth factor receptor 2, HER-2(+), which decreases during the progression from in situ to invasive breast cancer [ 4 ]. Similarly, the estrogen receptor (ER) status changes from a predominant ER(+) state in pure DCIS to a lower percentage of ER(+) tumors as DCIS progresses and develops micro-invasions [ 5 , 6 ]. The availability of established breast ductal carcinoma in situ cell lines that resemble the genetic heterogeneity and molecular subtypes of the human disease is limited.…”

Section: Introductionmentioning

confidence: 99%

Diallyl Trisulfide Induces Apoptosis in Breast Ductal Carcinoma In Situ Derived and Minimally Invasive Breast Cancer Cells

Stan

Abtahi

2022

Nutrients

View full text Add to dashboard Cite

Breast ductal carcinoma in situ (DCIS) is a localized form of breast cancer that can progress to invasive breast cancer. Diallyl trisulfide (DATS) is a bioactive compound from Allium vegetables reported to induce anticancer effects in several cancer models. The objective of this study was to characterize DATS-induced apoptosis in breast DCIS and minimally invasive breast cancer cells. Breast DCIS cells SUM 102PT (ductal carcinoma in situ with areas of micro-invasion) and SUM 225CWN (chest wall recurrence of ductal carcinoma in situ) were used in this study. DATS induced a dose-dependent reduction in the colony formation ability of breast DCIS cells. DATS inhibited DCIS cell growth by inducing apoptosis as shown by a dose-dependent increase in cytoplasmic histone-associated DNA fragmentation. Induction of apoptosis was more pronounced in SUM 102PT cells than in SUM 225CWN cells at similar concentrations of DATS. DATS-induced apoptosis was characterized by a dose-dependent increase in cleaved poly-ADP ribose polymerase (PARP). DATS treatment resulted in an increase in the cytochrome c levels and cleavage of caspases 3, 7, and 9. This study shows that DATS inhibits cell proliferation and induces apoptosis in breast DCIS derived and minimally invasive breast cancer cells, and supports further investigation of DATS as a potential chemopreventive agent for DCIS.

show abstract

“…Fortunately, a review 7 in recent years described relevant literature regarding the characteristics, diagnosis, treatment, and prognosis of DCIS‐MI, particularly with regard to surgical options (local treatment and management of axillary lymph nodes).…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological characteristics, treatments, and prognosis of breast ductal carcinoma in situ with microinvasion: A narrative review

Zhang

Cui³

2022

Chronic Diseases and Translational Medicine

View full text Add to dashboard Cite

Background: Ductal carcinoma in situ with microinvasion (DCIS-MI) is defined as ductal carcinoma in situ (DCIS) with a microscopic invasive focus ≤1 mm in the longest diameter. The current literature is controversial concerning the clinical prognostic features and management of DCIS-MI. This narrative review described recently reported literature regarding the characteristics, treatment, and prognosis of it. Methods: Searching PubMed for relevant articles covering the period of 1982 to 2021 using the following terms by MeSH and free-word: breast cancer, microinvasion, DCIS, DCIS-MI, and invasive ductal carcinoma (IDC). Results: DCIS-MI tends to express more aggressive pathological features such as necrosis, HER2+, ER-or PR-, and high nuclear grade. The overall prognosis of DCIS-MI is typically good, however, some indicators such as young age, HR-, HER2+ and multimicroinvasive lesions, were associated with worse prognoses. And there are also conflicting results on the differences between the prognoses of DCIS-MI and DCIS or T1a-IDC. Postoperative chemotherapy and anti-HER2 therapy still have uncertain benefits and are more likely to be used to treat high-risk patients who are HR-orHER2+ to improve the prognosis. Conclusion: DCIS-MI has more aggressive pathological features, which may suggest its biological behavior is worse than that of DCIS and similar to early IDC. Although the overall prognosis of DCIS-MI is good, when making decisions about adjuvant therapy clinicians need to give priority to the hormone receptor status, HER2 expression and axillary lymph node status of patients, because these may affect the prognosis and treatment response. K E Y W O R D S breast cancer, ductal carcinoma in situ, microinvasion, pathological features, treatment Highlights • Focusing summary on the relationship between adverse prognostic factors and treatment • Discussing treatment according to different subtypes and lymph node status combined with National Comprehensive Cancer Network guidelines • Including the most recent and representative clinical research to strive for accuracy and timeliness Chronic Dis Transl Med.

show abstract

Clinical characteristics of breast ductal carcinoma in situ with microinvasion: a narrative review

Cited by 16 publications

References 41 publications

Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population‐based analysis

Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population‐based analysis

Diallyl Trisulfide Induces Apoptosis in Breast Ductal Carcinoma In Situ Derived and Minimally Invasive Breast Cancer Cells

Clinicopathological characteristics, treatments, and prognosis of breast ductal carcinoma in situ with microinvasion: A narrative review

Contact Info

Product

Resources

About